Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$3.06
-2.2%
$2.56
$2.15
$7.77
$13.62M1.4227,708 shs12,702 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.72
+10.8%
$0.79
$0.57
$2.48
$14.55M1.051.00 million shs1.54 million shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$1.12
-0.9%
$1.22
$0.81
$4.19
$13.13M0.84143,762 shs108,115 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$2.01
-14.1%
$2.31
$1.73
$7.05
$3.62M0.83.75 million shs88,814 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-2.24%-1.29%+25.67%+4.44%-0.97%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+10.77%+10.07%-12.62%-5.91%-23.24%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-0.88%-1.75%-13.18%-32.12%-39.78%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-14.10%-24.15%-7.37%-8.01%-61.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$3.06
-2.2%
$2.56
$2.15
$7.77
$13.62M1.4227,708 shs12,702 shs
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$0.72
+10.8%
$0.79
$0.57
$2.48
$14.55M1.051.00 million shs1.54 million shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$1.12
-0.9%
$1.22
$0.81
$4.19
$13.13M0.84143,762 shs108,115 shs
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
$2.01
-14.1%
$2.31
$1.73
$7.05
$3.62M0.83.75 million shs88,814 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-2.24%-1.29%+25.67%+4.44%-0.97%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
+10.77%+10.07%-12.62%-5.91%-23.24%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-0.88%-1.75%-13.18%-32.12%-39.78%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-14.10%-24.15%-7.37%-8.01%-61.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLineRx Ltd. stock logo
BLRX
BioLineRx
2.67
Moderate BuyN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.00
Hold$6.00733.33% Upside
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.00
Hold$14.001,150.00% Upside
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest XRTX, CTXR, BLRX, and PHIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
Reiterated RatingSell (E+)
4/20/2026
BioLineRx Ltd. stock logo
BLRX
BioLineRx
Reiterated RatingSell (E+)
3/27/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingSell (E+)
3/27/2026
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
Reiterated RatingSell (E+)
3/11/2026
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
Reiterated RatingBuy$6.00
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$1.18M11.28N/AN/A$5.36 per share0.57
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$4.29 per shareN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$1.42 per shareN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/A$1.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$1.17M-$0.17N/AN/AN/A-99.58%-5.61%-2.81%5/26/2026 (Estimated)
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$37.43M-$2.45N/AN/AN/AN/A-49.34%-28.64%N/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%5/21/2026 (Estimated)
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
-$2.66M-$3.00N/AN/AN/AN/A-120.32%-90.53%N/A

Latest XRTX, CTXR, BLRX, and PHIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/26/2026Q1 2026
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$1.04N/AN/AN/A$0.34 millionN/A
5/21/2026Q1 2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.24N/AN/AN/AN/AN/A
5/7/2026Q1 2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.24-$0.34-$0.10-$0.34N/AN/A
3/24/2026Q4 2025
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$0.50-$0.34+$0.16N/A$0.49 million$0.19 million
3/5/2026Q4 2025
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.34-$0.15+$0.19-$0.15N/AN/A
2/26/2026Q4 2025
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A-$0.45N/A-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioLineRx Ltd. stock logo
BLRX
BioLineRx
N/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.19
1.95
1.78
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.99
0.40
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
18.32
18.32
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A
2.11
2.11

Institutional Ownership

CompanyInstitutional Ownership
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.56%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
0.23%

Insider Ownership

CompanyInsider Ownership
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.10%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
4.99%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.89%
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLineRx Ltd. stock logo
BLRX
BioLineRx
404.35 million4.30 millionOptionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2022.38 million21.26 millionOptionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
1011.62 million11.51 millionNot Optionable
XORTX Therapeutics Inc. stock logo
XRTX
XORTX Therapeutics
N/A1.55 million1.30 millionNot Optionable

Recent News About These Companies

XORTX Announces US$5 Million Public Offering
XORTX Announces US$5 Million Public Offering
XORTX Meets Nasdaq Continued Listing Requirements
XORTX Confirms Effective Date of Share Consolidation
XORTX Confirms Effective Date of Share Consolidation
XORTX Confirms Effective Date of Share Consolidation

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLineRx stock logo

BioLineRx NASDAQ:BLRX

$3.06 -0.07 (-2.24%)
Closing price 05/14/2026 03:59 PM Eastern
Extended Trading
$3.06 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$0.72 +0.07 (+10.77%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$0.74 +0.02 (+2.08%)
As of 05:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$1.12 -0.01 (-0.88%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$1.12 0.00 (0.00%)
As of 05:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

XORTX Therapeutics stock logo

XORTX Therapeutics NASDAQ:XRTX

$2.01 -0.33 (-14.10%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$2.14 +0.13 (+6.52%)
As of 05:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.